News | July 27, 2009

Prescient Medical Receives Frost & Sullivan Innovation of the Year Award for Vulnerable Plaque Stent, Imaging System

July 27, 2009 – Prescient Medical Inc. received the prestigious 2009 North American Product Innovation of the Year Award from Frost & Sullivan for Atherosclerosis Lesion Management, for its efforts to reduce deaths related to heart attacks using the vProtect Luminal Shield.

Heart attacks are now widely believed to occur when so-called "vulnerable plaque” ruptures, releasing cholesterol and cellular debris into the blood stream and potentially causing a clot that disrupts blood flow to the heart. The vProtect Luminal Shield is a self-expanding nitinol device designed to treat soft, recently ruptured and at-risk lesions in coronary arteries. Clinical evaluation of the Shield, which has not yet received marketing approval, is proceeding rapidly.

"This unique catheter-based, guidewire-deliverable device supports the body's natural healing process and promotes growth of endothelial cells over the lesion's thin fibrous cap to prevent it from rupturing," explained Bhavatharini Rajesh, research analyst, Frost & Sullivan.

The vProtect Luminal Shield recently completed phase I first-in-human trials for the treatment of de novo obstructive coronary lesions. The Shield is also being evaluated in an investigator-sponsored study known as the SECRITT I (Santorini Criteria for Investigating and Treating Thin Capped Fibroatheroma) trial for the treatment of vulnerable plaques, and a separate study is planned to evaluate use of the Shield in patients with acute coronary syndromes (ACS).

A second Prescient Medical product, the vPredict Optical Catheter System, is being developed for the detection of vulnerable plaque. It will be evaluated in tandem with the vProtect Luminal Shield in the PRESCIENT (Predictive use of Spectroscopic tissue Classification In Evaluating a Novel Treatment) trial, an ambitious study designed to evaluate the detection and prophylactic treatment of vulnerable plaques.

“The vProtect Luminal Shield should revolutionize the management of atherosclerotic lesions and prove to be a boon for interventional cardiologists and, most importantly, for patients by improving their quality of life and outcome," Rajesh said.
Previous Frost & Sullivan award recipients include Boston Scientific for the 2008 United States Coronary Stent Market Leadership Award and Bristol-Myers Squibb for the 2008 United States Breast Cancer Therapeutics Product Innovation of the Year Award.

For more information: www.prescientmedical.com

Related Content

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init